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Abstract: The Philadelphia chromosome (Ph)-negative myeloproliferative neoplasms (MPNs), 
including polycythemia vera, essential thrombocythemia, and primary myelofibrosis, are a 
group of clonal hematopoietic stem cell disorders with overlapping clinical and cytogenetic 
features and a variable tendency to evolve into acute leukemia. These diseases not only share 
overlapping chromosomal abnormalities but also a number of acquired somatic mutations. 
Recently, mutations in a putative tumor suppressor gene, ten-eleven translocation 2 (TET2) 
on chromosome 4q24 have been identified in 12% of patients with MPN. Additionally 4q24 
chromosomal rearrangements in MPN, including TET2 deletions, have also been observed 
using conventional cytogenetics. The goal of this study was to investigate the frequency of 
genomic TET2 rearrangements in MPN using fluorescence in situ hybridization as a more 
sensitive method for screening and identifying genomic deletions. Among 146 MPN patients, 
we identified two patients (1.4%) who showed a common 4q24 deletion, including TET2. Our 
observations also indicated that the frequency of TET2 deletion is increased in patients with an 
abnormal karyotype (5%).
Keywords: TET2, myeloproliferative neoplasms, fluorescence in situ hybridization, 
cytogenetics
Introduction
The Philadelphia chromosome negative (Ph-) myeloproliferative neoplasms (MPNs) 
are a group of clonal hematopoietic stem cell disorders with overlapping clinical 
and cytogenetic features and a variable tendency to evolve into acute leukemia. 
The Ph- MPNs include polycythemia vera, essential thrombocythemia, and primary 
myelofibrosis. The current unifying concept of cytogenetic instability of Ph- MPN 
is a loss or gain of chromosomal regions. The most frequent recurrent chromosomal 
abnormalities occurring in the Ph- MPNs include trisomy 9/+9p, deletion (20) (q11q13), 
deletion of 13q, and trisomy of chromosomes 8 and 9. The prognostic significance of 
the abnormalities in MPNs remains uncertain. However, recent attempts have been 
made to classify cytogenetic findings in primary myelofibrosis patients as being asso-
ciated with favorable [isolated deletion (20q) and 13q, trisomy 9 as well as normal 
karyotype] outcomes and unfavorable outcomes (all other chromosome abnormalities). 
The number of patients remains too small and the time of follow-up too limited for 
a definitive validation of the outcomes associated with chromosomal risk profiles.1 
Nevertheless, it appears that the presence of cytogenetic abnormalities in primary 
myelofibrosis is associated with shorter survival, but their independent contribution 





Besides cytogenetic abnormalities, these diseases also 
share acquired somatic mutation of JAK2 in exon 14, 
resulting in a valine to phenylalanine substitution in codon 
617, JAK2V617F, present in over 90% of patients with poly-
cythemia vera, 60% of patients with essential thrombocythemia, 
and 50% of patients with primary myelofibrosis.3–6 Although 
most MPNs carry mutation on one of two alleles, 2.8% of 
MPNs acquire JAK2V617F on two JAK2 alleles,7 and 3% 
of JAK2V617F-negative patients have mutations in exon 12 
of JAK2.8 Coexistence of these two mutations have also been 
described.9 MPL mutations leading to MPLW515L occur in 
5%–10% of patients with primary myelofibrosis and in 2%–5% 
of patients with essential thrombocythemia who are negative 
for JAK2V617F.10,11 Other mutations described in MPN patients 
include mutations of the CBL and ASXL1 genes.12,13
Recently, somatic mutations and deletions of the ten-
eleven translocation 2, or TET2, a putative tumor suppressor 
gene located on chromosome 4, band q24, have been described 
in 12% of patients with MPN.14 TET2 mutations may predate 
the JAK2V617F mutation, may occur after the acquisition 
of JAK2V617F, or may occur simultaneously in two dif-
ferent clones.14,15 Following the original description, TET2 
nonsense and splice mutations,   deletions, and out-of-frame 
insertions were identified in other myeloid malignancies, 
including myelodysplastic syndrome (19%–26%), de novo 
acute myeloid leukemia (12%–20%), therapy-related acute 
myeloid leukemia (24%–43%), chronic myelomonocytic leu-
kemia (20%–51%), and systemic mastocytosis (29%).14,16–24 
Although the current prognostic value of TET2 mutations in 
MPNs remains unknown, TET2 mutations were reported in 
6/14 patients (43%) with MPN who had transformed to acute 
myeloid leukemia.25
Deletions of the 4q24 region, including the TET2 gene, 
have been identified by conventional cytogenetics. In 2005, 
Viguie et al reported a common deletion of 4q24 in four 
patients with acute myeloid leukemia/myelodysplastic syn-
drome.26 Additional cytogenetic and high-resolution single-
nucleotide polymorphism karyotyping revealed that 20/886 
(2%) patients with myeloid disorders exhibited either partial 
or complete deletion of TET2.14,18–20 In at least four patients 
with acute myeloid leukemia/myelodysplastic syndrome, the 
remaining TET2 copy harbored a somatic mutation.19 More 
recently, Hussein compared cytogenetic findings with TET2 
status and concluded that unmutated TET2 MPN patients 
were not cytogenetically different from those MPN patients 
who harbor TET2 mutations, but there was no information 
provided regarding deletions of 4q24/TET2.27
Materials and methods
Patients
A total of 146 patient samples (48 were obtained from the 
Myeloproliferative Disorders-Research Consortium Tissue 
Bank) were entered in this study, including myelofibrosis 
(n = 52), polycythemia vera (n = 47), essential thrombo-
cythemia (n = 21), myeloproliferative neoplasm (unclassi-
fied, MPNu, n = 20), and MPNu/myelodysplastic syndrome 
(n = 6). After patient informed consent was obtained, 
peripheral blood and bone marrow specimens were collected 
according to the Institutional Review Board guidelines of the 
Mount Sinai School of Medicine.
Bacterial artificial chromosome clones
Three bacterial artificial chromosome (BAC) clones, 
  RP11-912N16 (137 kb), RP11-16G16 (175 kb), and 
RP11-45L9 (162 kb) obtained from BACPAC Resources, 
  Oakland, CA, were grown on chloramphenicol agar plates. 
The BAC clone RP11-16G16 contains the commonly 
deleted region on 4q24, including TET2. To determine the 
extent of the deletion or possible rearrangements of the 
4q24 region, two additional BAC clones, RP11-912N16 
and   RP11-45L9, containing DNA segments centromeric 
and telomeric to this commonly deleted region, respec-
tively, were also used. Selected positive colonies were 
harvested after overnight growth using the Qiagen Large-
Construct kit (Qiagen, Valenica, CA). DNA labeling was 
achieved using the CGH Nick Translation Kit (Abbott 
Molecular, Des Plaines, IL) and was fluorescently labeled 
with spectrum green (RP11-912N16), spectrum aqua 
(RP11-16G16), and spectrum red (RP11-45L9) according 
to the Abbott Molecular CGH protocol (Abbott Molecular). 
Validation fluorescence in situ hybridization (FISH) stud-
ies for all three BAC clones were performed on normal 
controls by evaluating 2000 interphase nuclei. The cutoff 
percentage for these probes was 3.5% and was calculated 
by using the mean ± three standard deviations. All three 
BAC probes mapped to the 4q24 region in 40 examined 
metaphase cells, demonstrating the 100% specificity of 
these probes. In interphase nuclei of normal cells, the 
expected normal probe signals appear as two tricolor 
(green, red, aqua) fusions.
Cytogenetic and Fish analysis
FISH analysis was performed as previously described with 




TET2 deletions in myeloproliferative neoplasms
2 mL 1% HCl) for five minutes.28 Codenaturation of cells 
and FISH probes were carried out on a Thermobrite (Abbott 
Molecular) for three minutes at 73°C and hybridized at 37°C 
overnight. A total of 200 nuclei were scored in each of the 
146 specimens. Metaphase cells were obtained using stan-
dard cytogenetic methods. Chromosomal abnormalities were 
described according to the International System of Human 
Cytogenetic Nomenclature (2009).29
Results
We investigated 146 patients with Ph- MPN to determine 
the frequency of TET2 genomic rearrangements. The sum-
mary of FISH studies, using the three TET2 BAC FISH 
probes as well as the cytogenetic results, are provided in 
Table 1. Chromosomal analyses were available for 83/146 
(57%) patients; 44 (53%) patients had a normal karyotype 
and 39 (47%) had an abnormal karyotype. The frequency 
of chromosomal abnormalities among the 39 patients with 
an abnormal karyotype were: deletion of the long arms of 
chromosome 20 in 11/39 (29%), followed by +9/+i(9p) in 
9/39 (24%), trisomy of chromosome 8 in 7/39 (18%), and 
trisomy of the long arms of chromosome 1 in 6/39 (16%). 
Abnormalities of 4q24 (deletions, translocations, or dupli-
cations) were not detected in any of the 39 patients with an 
abnormal karyotype by conventional cytogenetics. Inter-
phase FISH analysis using these probes revealed   deletion 
of TET2 in 2/83 patients (2% of total, and 5% among cyto-
genetically abnormal).
Patient 34 with primary myelofibrosis was JAK2V617F+ 
and had a complex karyotype, but 4q24 rearrangement was not 
identified (see Table 2). Interphase FISH with TET2 revealed 
a deletion of all three BAC probes in 5% of interphase nuclei. 
The follow-up peripheral blood specimen eight months later 
revealed 30% of interphase cells with a TET2 deletion, as well 
as a clone with a cytogenetically identified deletion of the 4q24 
region (see Figure 1). Patient 8, with primary myelofibrosis, 
was JAK2V617F+, had a normal karyotype (see Table 2), and 
was disomic for the following loci: 7p11.1–q11.1, 8p11.1–
q11.1, 9p11.1–q11.1, 1q12, 1q21, 1p36, 1q25, 5p15.2, 5q31, 
7q31, 9p21 13q14, and 20q12 using interphase FISH. These 
loci are most frequently rearranged in MPN. In contrast, 
90% of interphase cells revealed a deletion of only the RP11-
16G16 BAC probe, and not RP11-912N16 and RP11-45L9, 
indicating a small interstitial TET2 deletion of at least 175 kb 
localized between the centromeric and telomeric BAC FISH 
probes (see Figure 1).
Based on these initial studies, we screened an additional 
63 patients for TET2 genomic rearrangements, as shown in 
Table 1, and none were identified.
Table 1 also shows JAK2 status in 42 patients and 
MPLW515L mutational status in 16 patients. Of the three 
patients who had TET2 deletion, one was MPLW515L 
mutation-negative, and the MPL mutational status of the 
remaining two patients was not available.
Among 22,500 cytogenetically examined patients at our 
institution we identified only three patients with 4q24 chromo-
somal rearrangements, two with myelodysplastic syndrome 
and one with primary myelofibrosis (#34), indicating their rare 
occurrence. Patient 34 was identified among 512 patients with 
MPN (polycythemia vera = 361, myelofibrosis = 151). We 
therefore used interphase FISH as a more sensitive method 
to detect 4q24 chromosomal rearrangements and identified 
an additional patient of the 146 tested patients with TET2 
deletion, confirming the published frequency of 1%–2% 
in MPNs.14,18 However, among patients with available con-
ventional cytogenetic results, the frequency was 2% overall 
(2/83), or 5% (2/39) among the cytogenetically abnormal 
patients. Two patients had primary myelofibrosis, while none 
of the 47 patients with polycythemia vera nor 21 patients with 
essential thrombocythemia had TET2 deletions.
Table 1 interphase Fish detection of TET2 deletion




normal 15 14 6 8 1 44
Abnormal 25 8 2 2 2 39
nD 12 25 13 10 3 63
Total 52 47 21 20 6 146
JAK2 status
JAK2V617F 4 16 9 0 0 29
JAK2 wt 6 1 5 0 0 12
nD 42 30 7 20 6 105
Total 52 47 21 20 6 146
MPL status
MPLW515L 0 1 1 0 0 2
MPL wt 2 4 7 0 0 13
nD 50 42 13 20 6 131
Total 52 47 21 20 6 146
TET2 status
TET2+ 2 0 0 0 0 2
TET2- 50 47 21 20 6 144
Total 52 47 21 20 6 146
Notes: (+) deletion; (-) I-FISH did not detect deletion of three bacterial artificial 
chromosomes.
Abbreviations: FISH, fluorescence in situ hybridization; MPnu, myeloproliferative 
neoplasm  (unclassified);  ND,  not  done;  wt,  wild  type;  MDS,  myelodysplastic 
syndrome; eT, essential thrombocythemia; PV, polycythemia vera; PMF, primary 





The size of the deletions varied. In one patient (#8) with 
a normal karyotype, a deletion of approximately 175 kb in 
90% of interphase nuclei containing the commonly deleted 
region of 4q24 (the other two BACs outside the region 
remained intact) was identified. This observation suggests a 
submicroscopic (cryptic) deletion beyond the resolution of 
conventional cytogenetic analysis and confirms the impor-
tance of using a higher resolution methodology for identi-
fying TET2 deletion. Moreover, metaphase FISH analysis 
confirmed a submicroscopic 4q24 deletion that was not 
detectable by conventional cytogenetics. The other patient 
(#34) had a deletion of all three BACs, resulting in a loss of 
at least 1.6 Mb. Interestingly, patient 34 had initially 5% of 
interphase cells with TET2 deletion that was not detectable 
by conventional cytogenetics. When 30% of his peripheral 
blood cells showed loss of TET2, a new complex cytogenetic 
clone emerged showing der(4)del(4)(p14)del(q24), resulting 
in a complete 4q24 deletion.
Heterozygous TET2 mutations have been rarely identi-
fied in patients with chronic myelogenous leukemia but 
were detected in those patients who progress to blast crisis 
or accelerated phase.30 Interpretation of these observations 
suggested that TET2 mutations represent secondary lesions 
which contribute to the progression of the disease.30 We 
identified one patient with chronic myelogenous leukemia, 
not included in this study, who had complex chromosomal 
aberrations consistent with blast crisis of chronic myelog-
enous leukemia. FISH analysis revealed a complete deletion 
of all three BAC probes in 17% of interphase nuclei.
In summary, TET2 deletions are not a frequent genomic 
event in MPN. Their deletions are present in about 2% of   
MPN patients and, in those with increased karyotype 
Figure 1 interphase nuclei representing TET2 Fish signal patterns. A) normal nuclei with two triple color fusion signals. B) Deletion of the 175 kb RP11-16g16 BAC probe 
(aqua). C) Deletion of all three bacterial artificial chromosome probes; note only one triple color fusion signal.
Table 2 summary of results from two patients with TET2 deletions
Pt # Dx Mutational status TET2 BACs % of nuclei Karyotype
JAK2V617F MPLW515L RP11-912N16 RP11-16G16 RP11-45L9
8 PMF + nD + - + 90 46,XY





Notes: On a subsequent follow-up specimen a clone with the karyotype 45,XY,der(4)del(4)(p14)del(q24),-7,del(8)(p21)del(10)(q22),add(17)(p11.2),del(20(q11q13) had 
developed.
Abbreviations: ND, not done; PMF, primary myelofibrosis; BACs, bacterial artificial chromosomes.Cancer Management and Research
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  instability, they may occur in about 5% of patients. These 
observations may add supporting evidence that TET2 
mutations, as well as deletions, may contribute to leuke-
mic   evolution in patients with MPN that transform into 
leukemia.
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